Qiagen (QIA) Stock Overview
Provides sample to insight solutions that transform biological samples into molecular insights worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
QIA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Qiagen N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.36 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.42 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | 17.85% |
| 5 Year Change | 20.17% |
| Change since IPO | 126.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| QIA | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.7% |
| 1Y | 0% | 6.1% | 19.1% |
Return vs Industry: QIA exceeded the Swiss Life Sciences industry which returned -4.9% over the past year.
Return vs Market: QIA exceeded the Swiss Market which returned -3.1% over the past year.
Price Volatility
| QIA volatility | |
|---|---|
| QIA Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.7% |
| 10% least volatile stocks in CH Market | 2.1% |
Stable Share Price: QIA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QIA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 5,361 | Thierry Bernard | www.qiagen.com |
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen N.V. Fundamentals Summary
| QIA fundamental statistics | |
|---|---|
| Market cap | CHF 8.43b |
| Earnings (TTM) | CHF 311.89m |
| Revenue (TTM) | CHF 1.80b |
Is QIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QIA income statement (TTM) | |
|---|---|
| Revenue | US$1.97b |
| Cost of Revenue | US$667.43m |
| Gross Profit | US$1.30b |
| Other Expenses | US$956.58m |
| Earnings | US$341.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 1.54 |
| Gross Margin | 66.04% |
| Net Profit Margin | 17.37% |
| Debt/Equity Ratio | 42.2% |
How did QIA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/27 16:40 |
| End of Day Share Price | 2024/01/29 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Qiagen N.V. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |